Journal
Compounded vs Brand: The Price Gap Has Collapsed
The discount that built this market is far smaller than it was in 2023.
The discount that built this market is far smaller than it was in 2023. This piece sets out what is established on compounded vs brand glp1 cost, which record holds it, and what remains unverified — with the underlying figures published as tables and charts so the reasoning is checkable rather than asserted.
Key findings
- The discount that built this market is far smaller than it was in 2023.
- Every figure here is drawn from a dated capture or an FDA primary source.
- Regulatory framework and entity-specific claims are held to different evidence standards.
- Open fields render as explicit statuses, never as estimates.
- No provider pays for coverage or placement on this platform.
| Topic | compounded vs brand glp1 cost |
|---|---|
| Category | Cost |
| Pricing captured | 2026-07-06 |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
The gap that built this market has closed
In 2023 the compounded discount against brand pricing was several hundred dollars a month. Brand self-pay pricing fell sharply through late 2025 — NovoCare cut Wegovy maintenance from $499 to $349 in November alone.
The residual risk of an unapproved preparation with no premarket review is now being accepted for a much smaller discount, and in many cases for none at all.
What the number on the page leaves out?
Three things separate an advertised figure from what leaves your account. A required membership adds to every month — Eden quotes $99 for compounded semaglutide, but the membership is mandatory, so the real figure is $198. An introductory rate applies to one month; eleven of the 92 offerings in this dataset are first-month prices. And a committed-plan rate is not a month-to-month rate.
Every figure on this platform is a total: medication plus any membership that cannot be declined, computed as plan total divided by plan months. That is the only basis on which two programmes can be compared at all.
| # | Provider | Total / month | Format | Notes |
|---|---|---|---|---|
| 1 | NexLife | $110 | Injectable | Microdose, 12-month ($1,320). M2M $129. No membership, flat at every covered dose. Below every dose studied in |
| 2 | Oak Longevity | $133 | Injectable | Flat across doses, no subscription. Not available in California. |
| 3 | NexLife | $145 | Injectable | Standard injection, 12-month ($1,740). M2M $165. No membership, flat at every covered dose. |
| 4 | Shed | $149 | Injectable | Microdose programme. 2-month minimum. |
| 5 | NexLife | $165 | Oral / ODT | ODT, 12-month ($1,980). M2M $199. No trial has tested this dosage form. |
| 6 | Found | $169 | Injectable | 12-month prepaid. Medication included, flat across doses. |
| 7 | Shed | $175 | Injectable | 12-month prepaid. Increases at higher doses. |
| 8 | Mochi Health | $178 | Injectable | Membership required. Same price at all doses. |
| 9 | Henry Meds | $179 | Sublingual | Sublingual tablets or drops. |
| 10 | Eden | $198 | Injectable | Membership required for any medication. |
The comparison that changed
For three years the compounded case rested on a large discount against brand pricing. That gap has narrowed to the point where it no longer reliably exists.
An FDA-approved oral GLP-1 is now $149 per month — Foundayo via LillyDirect, or the Wegovy tablet via NovoCare. Most of the compounded market sits between $169 and $399. An approved, premarket-reviewed, manufacturer-supplied medication now undercuts the majority of compounded programmes, and almost no comparison site has caught up.
Chart data as a table
| NexLife ★ | 147 |
|---|---|
| Found | 169 |
| Enhance.MD | 169 |
| NexLife ★ | 186 |
| Shed | 199 |
| Oak Longevity | 199 |
| NexLife ★ | 199 |
| Shed | 229 |
| Shed | 245 |
| Mochi Health | 278 |
What to establish before prepaying?
A twelve-month commitment converts a clinical uncertainty into a financial one. Gastrointestinal effects end treatment for a measurable share of people, so the question that matters is what happens to the unused balance if you stop in month two.
Get three things in writing: the cancellation notice period, whether unused prepaid months are refundable, and how auto-renewal is stopped. None of them is verified on this platform for any provider.
| FDA-approved route | Total / month | Format | Notes |
|---|---|---|---|
| LillyDirect — Foundayo (orforglipron) | $149 | Oral / pill | 0.8 mg starter. Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Rises to $199/$299/$349 by dose. |
| NovoCare — Wegovy tablet | $149 | Oral / pill | 1.5 mg and 4 mg. Cheapest verified path to FDA-approved oral semaglutide. |
| LillyDirect — Zepbound vial | $299 | Injectable | 2.5 mg starter. 5 mg $399; 7.5–15 mg $449. 45-day refill rule. |
| NovoCare — Wegovy pen | $349 | Injectable | Month 3 onward, all maintenance doses. Cut from $499 in November 2025. |
What would change this analysis?
Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.
None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.
How to check any of this yourself
Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.
Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.
Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.
Applying this to compounded vs brand glp1 cost
The discount that built this market is far smaller than it was in 2023.
Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.
What this means
- Regulatory framework and dates are cited to FDA primary sources.
- Pricing figures are dated captures against provider pages, computed as totals.
- Every open field carries an explicit status rather than an estimate.
What this does not mean
- That any named entity is compliant, safe, or non-compliant.
- That a lower price indicates better evidence or quality.
- That this platform certifies or endorses any facility or preparation.
- Pricing captured 2026-07-06; confirm at checkout before relying on it.
- Regulatory positions change through rulemaking, guidance and enforcement action.
- Entity-specific licence and enforcement records are covered on the monitoring pages, not here.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the short answer on compounded vs brand glp1 cost?
The discount that built this market is far smaller than it was in 2023.
Where do these figures come from?
Pricing from dated captures against provider pages (2026-07-06); regulatory facts from FDA primary sources.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
How often is this updated?
When the underlying capture or regulatory position changes. Every page carries its own date.
Is this legal or medical advice?
No. It reports what named public records say on the dates they were checked. Clinical decisions belong with a prescriber and legal questions with a qualified adviser.
How can I check the figures myself?
The pricing dataset is published as JSON and CSV, the FDA register and inspection records are linked on every page that uses them, and each figure carries its capture date.
What if a record here is wrong?
Report it through the corrections process. Named entities can also respond through the right-to-respond route, and accepted corrections are logged with their date.
Sources
- GLP-1 pricing database
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.